tiprankstipranks
pc:hansa

Hansa Biopharma AB

Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company leverages its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Hansa's portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy that facilitates kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG cleaving molecule with potential for redosing. Based in Lund, Sweden, Hansa Biopharma operates in Europe and the U.S. and is listed on Nasdaq Stockholm under the ticker HNSA.

Leadership & Board

Currently, no data available

Latest Estimated Valuation

Estimated Valuation
Estimated Valuation
Total Amount Raised$131M
Total Amount Raised$131M
Total Funding Rounds2
Total Funding Rounds2
Latest Funding Amount$60M
Latest Funding Amount$60M
Latest Funding RoundInvestment
Latest Funding RoundInvestment
Post-Money Valuation
Post-Money Valuation

Main Enterprise Clients

A snapshot of major enterprise customers that use this private company’s products or services, highlighting its commercial reach and market adoption.

Funding Round

Funding Date
Funding Round
Amount Raised
Post-Money Valuation
Oct 08, 2025
Investment
$60.00M
Oct 08, 2025
Investment
$71.30M

Investors

Investor Name
Funding Round
Investment

Related News and Analysis